Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
17.01
-0.04 (-0.21%)
Mar 31, 2025, 1:13 PM EDT - Market open
Fulgent Genetics Revenue
In the year 2024, Fulgent Genetics had annual revenue of $283.47M, down -1.99%. Fulgent Genetics had revenue of $76.21M in the quarter ending December 31, 2024, with 8.10% growth.
Revenue (ttm)
$283.47M
Revenue Growth
-1.99%
P/S Ratio
1.82
Revenue / Employee
$215,895
Employees
1,313
Market Cap
524.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 283.47M | -5.74M | -1.99% |
Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
FLGT News
- 11 days ago - Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy - Seeking Alpha
- 4 weeks ago - Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 4 weeks ago - Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 7 weeks ago - Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025 - Business Wire
- 7 weeks ago - Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics - Business Wire
- 3 months ago - Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside - Seeking Alpha
- 5 months ago - Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Fulgent Reports Third Quarter 2024 Financial Results - Business Wire